Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-675 inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-675 inhibitor refers to a class of therapeutic agents, typically antisense oligonucleotides (ASOs) or peptide nucleic acids (PNAs), designed to selectively bind and neutralize microRNA-675 (miR-675). miR-675 is a small non-coding RNA derived from the H19 long non-coding RNA (lncRNA) and is frequently upregulated in various cancers and physiological conditions. By inhibiting miR-675, these agents modulate downstream signaling pathways including Cdc25A, AKT/GSK-3β, and MITF. Research has explored miR-675 inhibitors for their potential in treating hepatocellular carcinoma (HCC) and osteosarcoma by suppressing cell proliferation and invasion. Additionally, experimental conjugates such as the placental homing peptide CCGKRK-miR-675 inhibitor have been investigated for targeted enhancement of placental growth in pregnancy complications like fetal growth restriction.
- Other names
- anti-miR-675anti-miR675anti-miR 675antagomir-675antagomir675antagomir 675microRNA-675 inhibitormicroRNA675 inhibitormicroRNA 675 inhibitor
02
Targets
miR-675-3p (MicroRNA 675-3p)miR-675-5p (MicroRNA 675-5p)
Beyond the preview
Go deeper on miR-675 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-675 inhibitor.